Project Grant R21CA302968
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$412K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $633,705 to the Mayo Clinic in Rochester, Minnesota to investigate mechanisms underlying resistance to PARP inhibitor (PARPi) drugs in prostate cancer. The research aims to identify strategies to overcome PARPi resistance, with a focus on the role of the NSD3S histone methyltransferase isoform in regulating DNA replication dynamics and contributing to PARPi resistance. The award...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a short RNA therapeutic to treat ovarian cancer at Nuago Therapeutics Inc. in Chicago, IL. The award will fund research to create a novel, targeted therapy that aims to induce DNA damage in ovarian cancer cells. This project, running from June 2025 through May 2026, seeks to advance a potential new treatment approach that could improve outcomes for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $800,888 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to evaluate a combination therapy approach for treating platinum resistant ovarian cancer. The project aims to assess the safety and tolerability of combining the CLK/DYRK inhibitor Cirtuvivint with the PARP inhibitor Olaparib in patients with BRCA/HRD deficiencies. The research...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $112,052 to The Trustees of the University of Pennsylvania to conduct research aimed at overcoming treatment resistance in gynecological cancers. The key products and services to be delivered include: Testing new therapies that exploit survival pathways critical for cancers with CCNE1 amplification, which are often platinum-resistant. This includes evaluating biomarkers beyond...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $371,070 to Resonant Therapeutics, Inc. to develop a novel nectin-targeting antibody-drug conjugate (ADC) for the treatment of ovarian cancer. The funding will be used to refine the target patient population, determine the optimal payload, and establish preclinical dosing for the ADC. This represents an important advancement, as current ADC treatments for ovarian cancer are...
This federal Project Grant award of $470,567.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Beth Israel Deaconess Medical Center, Inc. (BIDMC) aims to identify molecular features that influence response or resistance to PARP-inhibitor treatment in metastatic breast cancer patients without germline BRCA1/2 mutations. The award will fund analysis of pre-treatment tumor DNA and pre- and post-treatment circulating tumor DNA samples from 108 patients enrolled in...
This federal Project Grant award of $220,894 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to discover novel regulators of cellular deformability that can block the spread of chemoresistant ovarian cancer cells. The research will use a high-throughput cell filtration platform developed by the Rowat Laboratory at the University of California, Los Angeles (UCLA) to screen large libraries of small molecules and identify targets that can reverse the increased...
This $177,254 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports a 5-year research plan led by Dr. Ciara O'Sullivan at Mayo Clinic. The grant enables Dr. O'Sullivan to continue leading clinical trials testing new drugs and treatment strategies to overcome drug resistance in breast cancer, with a focus on endocrine-resistant and HER2-positive subtypes. Key activities include leading the COMPASSHER2 RD FDA registration trial,...
This $124,230 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research led by Dr. Parikh at the Mayo Clinic in Rochester, Minnesota. The key objectives are to: 1) Complete two ongoing clinical trials evaluating novel combination treatments for untreated chronic lymphocytic leukemia (CLL) patients, including data analysis and manuscript preparation; and 2) Develop the protocol and serve as the national principal investigator for...